Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Ney Carter Borges: Evaluating the True Symptomatic Benefit of PCI in Patients with CTO and Stable Angina
Ney Carter Borges/LinkedIn
Apr 4, 2026, 11:50

Ney Carter Borges: Evaluating the True Symptomatic Benefit of PCI in Patients with CTO and Stable Angina

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“ORBITA-CTO Trial — ACC 26

The ORBITA-CTO trial is the first randomized, double-blind, placebo – controlled study evaluating the true symptomatic benefit of percutaneous coronary intervention (PCI) in patients with chronic total occlusion (CTO) and stable angina.

Study Design

This multicenter UK trial randomized 50 patients with single-vessel CTO, documented ischemia, and viable myocardium to either:

  • CTO PCI (n=25)
  • Placebo procedure (n=25)

A rigorous blinding strategy was implemented using sedation and procedural simulation.

Anti-anginal therapy was withdrawn at randomization and reintroduced as needed.

Patients were followed for 6 months, with daily symptom tracking via a smartphone app (ORBITA-app).

Primary Outcome

The primary endpoint was a composite angina symptom score, integrating:

  • Daily angina frequency
  • Anti-anginal medication use
  • Clinical escalation events

Key Results

CTO PCI significantly improved angina compared with placebo:

  • OR 4.38 (95% CrI 1.57–12.69; probability of benefit = 0.996)

Reduction in angina episodes was the main driver:

  • OR 4.38 (95% CrI 1.55–11.78)

Patients undergoing PCI experienced:

  • Plus 30.6 additional angina-free days over 6 months

Secondary Outcomes

Consistent improvements were observed in:

Seattle Angina Questionnaire (SAQ):

Angina frequency: +10.7 points

Physical limitation: +13.5 points

Quality of life: +18.2 points

Summary score: +13.7 points

CCS angina class improved significantly

No meaningful benefit was seen in:

  • Dyspnea (NYHA, RDS)
  • Generic QoL (EQ-5D)

Interpretation

This trial provides definitive placebo-controlled evidence that:

  • CTO PCI yields a true physiological reduction in angina, not merely placebo effect
  • The magnitude of benefit is moderate but clinically meaningful
  • Symptom improvement is immediate and sustained

Importantly, a substantial placebo effect was also observed, reinforcing the need for blinded trials in interventional cardiology.

Clinical Implications

  • CTO PCI should be considered for symptomatic patients with demonstrable ischemia, especially in expert centers
  • Patient selection and shared decision-making remain critical
  • Benefits are primarily symptomatic, with no evidence for prognostic improvement

Take-Home Message

ORBITA-CTO establishes CTO PCI as an effective therapy for angina relief beyond placebo, with robust methodological validation – reshaping the evidence base for complex coronary revascularization.”

Ney Carter Borges

More posts featuring Ney Carter Borges on Hemostasis Today.

chronic total occlusion CTO Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Ney Carter Borges PCI percutaneous coronary intervention
NewsFeed